Business Context and Reporting Period
Company: Inmune Bio, Inc. (INMB)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: A clinical-stage biotechnology company focused on reprogramming the innate immune system. Key programs include CORDStrom (for Recessive Dystrophic Epidermolysis Bullosa), XPro1595 (for Alzheimer's Disease), and INKmune (for oncology). The company is a smaller reporting company with no revenue-generating commercial products.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $50 |
| Net Loss | $(5,407) | $(9,739) |
| Net Loss Per Share (Basic/Diluted) | $(0.20) | $(0.43) |
| Operating Expenses | $5,812 | $9,955 |
| Research & Development (R&D) | $3,641 | $7,639 |
| General & Administrative (G&A) | $2,171 | $2,316 |
| Cash and Cash Equivalents (End of Period) | $21,358 | $19,337 |
| Net Cash Used in Operating Activities | $(3,403) | $(6,824) |
| Total Assets | $25,818 | $32,351 |
| Total Liabilities | $6,194 | $8,827 |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by $4.3 million (44%) compared to Q1 2025, driven primarily by a significant reduction in R&D expenses.
- R&D Expense Decline: R&D expenses dropped $4.0 million. This was largely due to the completion of the Phase 2 Alzheimer's clinical trial in 2025, resulting in $4.5 million less in related expenses. This was partially offset by a $1.0 million increase in costs for CORDStrom and INKmune programs related to regulatory submission preparations.
- Cash Flow Improvement: Net cash used in operating activities improved by $3.4 million, aided by a $3.8 million decrease in the R&D tax credit receivable (indicating cash collections from Australian and UK tax incentives) and lower operating burn.
- Revenue: The company reported zero revenue in Q1 2026, compared to $50,000 in Q1 2025 from a prior license agreement.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. With $21.4 million in cash, the company projects insufficient liquidity to sustain operations for one year following the issuance of these financial statements.
- Financing Needs: The company is evaluating strategies to secure funding, including public or private equity sales, debt financing, government grants, or strategic collaborations. There is no assurance that additional capital will be available on favorable terms.
- Regulatory Milestones: The company intends to file a Marketing Authorization Application (MAA) in the UK and EU, followed by a Biologics License Application (BLA) with the FDA for CORDStrom, targeted for 2026.
- Recent Agreements: In April 2026 (subsequent to the period end), the company amended a license agreement with Anthony Nolan to secure a long-term supply of umbilical cord tissue for CORDStrom development.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the high cost of development, foreign currency fluctuations (AUD/GBP), and the potential inability to raise necessary capital.
Investor Verification Checklist
- Liquidity Runway: Verify the specific timeline for cash depletion and the status of any ongoing fundraising efforts or bridge financing.
- Regulatory Filings: Confirm the timeline and status of the planned MAA/BLA submissions for CORDStrom in 2026.
- Tax Credit Receivables: Monitor the collection status of remaining R&D tax credit receivables from Australia and the UK, which significantly impacted Q1 cash flow.
- Capital Structure: Review the outstanding warrants and stock options (approx. 13.7 million potentially issuable shares) for potential dilution in future financing rounds.
- Going Concern Mitigation: Assess the probability and terms of the financing strategies mentioned in the MD&A to determine if the going concern doubt can be alleviated.